• Research and Development

  Potential IPF Treatment, PLN-74809, Named Orphan Drug by FDA

  Posted by Pulmonary Fibrosis News Moderator on August 14, 2018 at 12:15 pm

  Pliant Therapeutics announced its lead IPF treatment candidate PLN-74809 now has orphan drug designation; clinical testing possible in 2019.

  Read more about this possible treatment here: FDA Names PLN-74809, Potential IPF Treatment, Orphan Drug to Speed Its Development

  What are your thought about this?

  replied 6 years, 6 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply